22157.jpg
Global Infection Surveillance Solutions Market is Forecast to Reach $1.03 Billion by 2026, Rising at a CAGR of 15.2%
October 01, 2021 04:58 ET | Research and Markets
Dublin, Oct. 01, 2021 (GLOBE NEWSWIRE) -- The "Global Infection Surveillance Solutions Market by Software (Cloud-based), Service (Product Support, Maintenance, Implementation), End-user (Hospitals...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection
June 29, 2021 13:58 ET | BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
EY Announces Dr. Susan L. Levinson of BioAegis Therapeutics Inc. as an Entrepreneur Of The Year® 2021 New Jersey Award Finalist
June 04, 2021 13:00 ET | BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 04, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
22157.jpg
Global Hospital Acquired Disease Testing Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts
May 27, 2021 06:58 ET | Research and Markets
Dublin, May 27, 2021 (GLOBE NEWSWIRE) -- The "Hospital Acquired Disease Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to...
The Joint Commission.jpg
Study identifies high-impact postoperative complications in older patients undergoing hip fracture repair
March 23, 2021 12:00 ET | Joint Commission
OAKBROOK TERRACE, Ill., March 23, 2021 (GLOBE NEWSWIRE) -- Hip fracture in older patients is common, debilitating and costly.1,2,3 A new study in the April 2021 issue of The Joint Commission Journal...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment
March 15, 2021 11:12 ET | BioAegis Therapeutics
MORRISTOWN, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
NIH and Other Independent Studies Confirm Low Levels of BioAegis’ ‘Inflammation Regulator Protein,’ Gelsolin, Associated with COVID-19 Severity
February 02, 2021 14:05 ET | BioAegis Therapeutics
MORRISTOWN, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Expands Phase 2 COVID-19 Treatment Clinical Trial in EU for Inflammation Regulator
November 15, 2020 19:35 ET | BioAegis Therapeutics
No drug-related safety signals identified by the independent Data and Safety Monitoring Board.MORRISTOWN, N.J., Nov. 15, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage,...
Eagle Hill School First to Use RxAir® UV Light Air Purifiers Campus-Wide to Combat Airborne Viruses
October 13, 2020 08:00 ET | Vystar Corp.
RxAir® UV-C Light inactivates 99.9% of airborne viruses, bacteria, mold & fungiTeachers more comfortable teaching in-person with RxAir in useVystar offering discounts to education institutions for...
BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia
September 03, 2020 21:42 ET | BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...